Rubix LS Joins a Nationwide Network Working to Accelerate Transformative Health Solutions
Lawrence, MA December 31, 2024 – Rubix LS, an independent research catalyst and translational Contract Research Organization announced today that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority-Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.
“This opportunity aligns perfectly with our mission at Rubix LS to transform health research into actionable and equitable outcomes for all communities,” said Reginald Swift, Founder and CEO of Rubix LS. “As a spoke in this vital network, we are excited to bring our unique platform capabilities and patient-centered approaches to advance ARPA-H’s transformative vision.”
Rubix LS joins a dynamic nationwide network of organizations aligned to ARPA-H’s overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. Investor Catalyst Hub spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.
“Our vibrant spoke network reflects a diverse range of experts with a shared commitment to closing gaps in innovation and health equity,” said Chelsea Schiller, Director of the Investor Catalyst Hub. “By building connections between our network and ARPA-H programs, we can help speed up the transition of innovative ideas into equitable health solutions for all.”
As an Investor Catalyst Hub spoke, Rubix LS gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities.
The spoke network will continue to grow as the Investor Catalyst Hub expands its efforts, with applications being selected on a rolling basis. Interested organizations can visit https://investorcatalysthub.org/ to learn more or submit a membership application.
About Rubix LS
Rubix LS is a research catalyst and translational Contract Research Organization (CRO) dedicated to executing dynamic and impactful clinical research and clinical trial programs. Focused on advancing health equity and addressing complex healthcare challenges, Rubix LS specializes in designing and implementing tailored studies from preclinical through Phase II trials.
Central to its approach is the Patient X platform, an integrative, interfaceless solution designed to simplify patient engagement and optimize data collection. Rubix LS also deploys its TRIDENT boots-on-the-ground team, a patient augmentation workforce that supports recruitment, retention, and social engagement in underserved communities. These capabilities ensure Rubix LS delivers actionable insights and scalable solutions with a focus on inclusivity and impact.
By combining robust data analytics, innovative methodologies, and a deep understanding of diverse patient populations, Rubix LS partners with academia, industry, and government to drive meaningful advances in healthcare. Through these efforts, Rubix LS transforms scientific innovation into real-world solutions that improve health outcomes and address disparities.
# # #